Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, Options, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 9-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 42)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 New Constructs, LLC N/A LLY: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 Pechala's Reports Lubomir Pechala ELI LILLY AND COMPANY (LLY=US) - REPORT FOR ACTIVE TRADERS 4 $25 View Abstract
9-Feb-10 ValuEngine, Inc. N/A ValuEngine Industry Report for DRUGS 18 $49 View Abstract
9-Feb-10 Stock Traders Daily Thomas H. Kee Jr. Trading Report for (LLY). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (LLY). 5 $18 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Plunkett's Health Care Technologies Overview 2010 (Summary) 80 $199 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Nanotechnology & MEMS Industry Trends, Statistics & Analysis 2009 (Summary) 34 $199 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Eli Lilly & Company (LLY) Profile & Biotech Industry Trends Analysis 2010 43 $149 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Nanotechnology & MEMS Industry Market Research and Competitive Analysis 2009 447 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
Next 20

Brokerage Reports (Showing 1 to 3 of 3)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
29-Jan-10 First Global Kavita Thomas, Devina Mehra First Global reiterates LT Moderate Outperform on Johnson & Johnson Inc. 14 $50 View Abstract
12-Jan-10 Thomson StreetEvents N/A LLY - Event Transcript of Eli Lilly conference call, Jan. 12, 2010 / 3:00pm ET 6 $75 View Abstract
30-Dec-09 First Global Kavita Thomas, Devina Mehra First Global reiterates Moderate Outperform on Sanofi-Aventis 15 $50 View Abstract

Independent Reports (Showing 1 to 10 of 39)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 New Constructs, LLC N/A LLY: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 Pechala's Reports Lubomir Pechala ELI LILLY AND COMPANY (LLY=US) - REPORT FOR ACTIVE TRADERS 4 $25 View Abstract
9-Feb-10 ValuEngine, Inc. N/A ValuEngine Industry Report for DRUGS 18 $49 View Abstract
9-Feb-10 Stock Traders Daily Thomas H. Kee Jr. Trading Report for (LLY). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (LLY). 5 $18 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Plunkett's Health Care Technologies Overview 2010 (Summary) 80 $199 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Nanotechnology & MEMS Industry Trends, Statistics & Analysis 2009 (Summary) 34 $199 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Eli Lilly & Company (LLY) Profile & Biotech Industry Trends Analysis 2010 43 $149 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Nanotechnology & MEMS Industry Market Research and Competitive Analysis 2009 447 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 569 $299 View Abstract
8-Feb-10 Plunkett Research, Ltd. Jack W. Plunkett Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) 71 $199 View Abstract
Next 20

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.